- Home
- SXTC vs TIL Comparison
SXTC vs TIL Comparison
Compare SXTC & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- TIL
- Stock Information
- Founded
- SXTC 2005
- TIL 2018
- Country
- SXTC China
- TIL United States
- Employees
- SXTC N/A
- TIL N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- TIL Health Care
- Exchange
- SXTC Nasdaq
- TIL Nasdaq
- Market Cap
- SXTC 184.5M
- TIL 177.1M
- IPO Year
- SXTC 2019
- TIL 2021
- Fundamental
- Price
- SXTC $1.36
- TIL $17.16
- Analyst Decision
- SXTC
- TIL Strong Buy
- Analyst Count
- SXTC 0
- TIL 5
- Target Price
- SXTC N/A
- TIL $100.67
- AVG Volume (30 Days)
- SXTC 25.6K
- TIL 87.3K
- Earning Date
- SXTC 08-19-2019
- TIL 11-13-2025
- Dividend Yield
- SXTC N/A
- TIL N/A
- EPS Growth
- SXTC N/A
- TIL N/A
- EPS
- SXTC N/A
- TIL N/A
- Revenue
- SXTC $1,740,907.00
- TIL N/A
- Revenue This Year
- SXTC N/A
- TIL N/A
- Revenue Next Year
- SXTC N/A
- TIL N/A
- P/E Ratio
- SXTC N/A
- TIL N/A
- Revenue Growth
- SXTC N/A
- TIL N/A
- 52 Week Low
- SXTC $0.95
- TIL $10.80
- 52 Week High
- SXTC $7.84
- TIL $42.79
- Technical
- Relative Strength Index (RSI)
- SXTC 40.70
- TIL 39.58
- Support Level
- SXTC $1.20
- TIL $18.10
- Resistance Level
- SXTC $1.43
- TIL $20.11
- Average True Range (ATR)
- SXTC 0.08
- TIL 1.38
- MACD
- SXTC -0.00
- TIL -0.03
- Stochastic Oscillator
- SXTC 53.33
- TIL 3.13
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.